Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: Results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model

Hwa Young Lee, Bong Min Yang, Ji Min Hong, Tae Jin Lee, Byoung Gie Kim, Jae Weon Kim, Young Tae Kim, Yong Man Kim, Sokbom Kang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: We performed a cost-utility analysis to assess the cost-effectiveness of a chemotherapy sequence including a combination of polyethylene glycolated liposomal doxorubicin (PLD)/carboplatin versus paclitaxel/carboplatin as a second-line treatment in women with platinum-sensitive ovarian cancer. Methods: A Markov model was constructed with a 10-year time horizon. The treatment sequence consisted of first- to sixth-line chemotherapies and best supportive care (BSC) before death. Cycle length, a time interval for efficacy evaluation of chemotherapy, was 9 weeks. The model consisted of four health states: responsive, progressive, clinical remission, and death. At any given time, a patient may have remained on a current therapy or made a transition to the next therapy or death. Median time to progressions and overall survivals data were obtained through a systematic literature review and were pooled using a meta-analytical approach. If unavailable, this was elicited from an expert panel (eg, BSC). These outcomes were converted to transition probabilities using an appropriate formula. Direct costs included drug-acquisition costs for chemotherapies, premedication, adverse-event treatment and monitoring, efficacy evaluation, BSC, drug administration, and follow-up tests during remission. Indirect costs were transportation expenses. Utilities were also derived from the literature. Costs and utilities were discounted at an annual rate of 5% per cycle. Results: PLD/carboplatin combination as the second line in the sequence is more effective and costly than paclitaxel/carboplatin combination, showing an additional US$21,658 per quality-adjusted life years. This result was robust in a deterministic sensitivity analysis except when median time to progression of second-line therapies and administration cost of PLD/carboplatin per administration cycle were varied. The probability of cost-effectiveness for PLD/carboplatin combination was 49.4% at a willingness to pay $20,000. Conclusion: A PLD/carboplatin combination is an economically valuable option as second-line chemotherapy for the treatment of platinum-sensitive ovarian cancer in South Korea.

Original languageEnglish
Pages (from-to)297-307
Number of pages11
JournalClinicoEconomics and Outcomes Research
Volume5
Issue number1
DOIs
Publication statusPublished - 2013 Jul 2

Fingerprint

Republic of Korea
Carboplatin
Polyethylene
Platinum
Ovarian Neoplasms
Cost-Benefit Analysis
Drug Therapy
Costs and Cost Analysis
Paclitaxel
Therapeutics
Drug Costs
Quality-Adjusted Life Years
Premedication
liposomal doxorubicin
Cost-utility analysis
Therapy
South Korea
Cancer
Chemotherapy
Sequencing

All Science Journal Classification (ASJC) codes

  • Economics, Econometrics and Finance (miscellaneous)
  • Health Policy

Cite this

Lee, Hwa Young ; Yang, Bong Min ; Hong, Ji Min ; Lee, Tae Jin ; Kim, Byoung Gie ; Kim, Jae Weon ; Kim, Young Tae ; Kim, Yong Man ; Kang, Sokbom. / Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea : Results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model. In: ClinicoEconomics and Outcomes Research. 2013 ; Vol. 5, No. 1. pp. 297-307.
@article{d7c0550a645c40eeab21421dddeec8cd,
title = "Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: Results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model",
abstract = "Objective: We performed a cost-utility analysis to assess the cost-effectiveness of a chemotherapy sequence including a combination of polyethylene glycolated liposomal doxorubicin (PLD)/carboplatin versus paclitaxel/carboplatin as a second-line treatment in women with platinum-sensitive ovarian cancer. Methods: A Markov model was constructed with a 10-year time horizon. The treatment sequence consisted of first- to sixth-line chemotherapies and best supportive care (BSC) before death. Cycle length, a time interval for efficacy evaluation of chemotherapy, was 9 weeks. The model consisted of four health states: responsive, progressive, clinical remission, and death. At any given time, a patient may have remained on a current therapy or made a transition to the next therapy or death. Median time to progressions and overall survivals data were obtained through a systematic literature review and were pooled using a meta-analytical approach. If unavailable, this was elicited from an expert panel (eg, BSC). These outcomes were converted to transition probabilities using an appropriate formula. Direct costs included drug-acquisition costs for chemotherapies, premedication, adverse-event treatment and monitoring, efficacy evaluation, BSC, drug administration, and follow-up tests during remission. Indirect costs were transportation expenses. Utilities were also derived from the literature. Costs and utilities were discounted at an annual rate of 5{\%} per cycle. Results: PLD/carboplatin combination as the second line in the sequence is more effective and costly than paclitaxel/carboplatin combination, showing an additional US$21,658 per quality-adjusted life years. This result was robust in a deterministic sensitivity analysis except when median time to progression of second-line therapies and administration cost of PLD/carboplatin per administration cycle were varied. The probability of cost-effectiveness for PLD/carboplatin combination was 49.4{\%} at a willingness to pay $20,000. Conclusion: A PLD/carboplatin combination is an economically valuable option as second-line chemotherapy for the treatment of platinum-sensitive ovarian cancer in South Korea.",
author = "Lee, {Hwa Young} and Yang, {Bong Min} and Hong, {Ji Min} and Lee, {Tae Jin} and Kim, {Byoung Gie} and Kim, {Jae Weon} and Kim, {Young Tae} and Kim, {Yong Man} and Sokbom Kang",
year = "2013",
month = "7",
day = "2",
doi = "10.2147/CEOR.S42170",
language = "English",
volume = "5",
pages = "297--307",
journal = "ClinicoEconomics and Outcomes Research",
issn = "1178-6981",
publisher = "Dove Medical Press Limited",
number = "1",

}

Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea : Results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model. / Lee, Hwa Young; Yang, Bong Min; Hong, Ji Min; Lee, Tae Jin; Kim, Byoung Gie; Kim, Jae Weon; Kim, Young Tae; Kim, Yong Man; Kang, Sokbom.

In: ClinicoEconomics and Outcomes Research, Vol. 5, No. 1, 02.07.2013, p. 297-307.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea

T2 - Results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model

AU - Lee, Hwa Young

AU - Yang, Bong Min

AU - Hong, Ji Min

AU - Lee, Tae Jin

AU - Kim, Byoung Gie

AU - Kim, Jae Weon

AU - Kim, Young Tae

AU - Kim, Yong Man

AU - Kang, Sokbom

PY - 2013/7/2

Y1 - 2013/7/2

N2 - Objective: We performed a cost-utility analysis to assess the cost-effectiveness of a chemotherapy sequence including a combination of polyethylene glycolated liposomal doxorubicin (PLD)/carboplatin versus paclitaxel/carboplatin as a second-line treatment in women with platinum-sensitive ovarian cancer. Methods: A Markov model was constructed with a 10-year time horizon. The treatment sequence consisted of first- to sixth-line chemotherapies and best supportive care (BSC) before death. Cycle length, a time interval for efficacy evaluation of chemotherapy, was 9 weeks. The model consisted of four health states: responsive, progressive, clinical remission, and death. At any given time, a patient may have remained on a current therapy or made a transition to the next therapy or death. Median time to progressions and overall survivals data were obtained through a systematic literature review and were pooled using a meta-analytical approach. If unavailable, this was elicited from an expert panel (eg, BSC). These outcomes were converted to transition probabilities using an appropriate formula. Direct costs included drug-acquisition costs for chemotherapies, premedication, adverse-event treatment and monitoring, efficacy evaluation, BSC, drug administration, and follow-up tests during remission. Indirect costs were transportation expenses. Utilities were also derived from the literature. Costs and utilities were discounted at an annual rate of 5% per cycle. Results: PLD/carboplatin combination as the second line in the sequence is more effective and costly than paclitaxel/carboplatin combination, showing an additional US$21,658 per quality-adjusted life years. This result was robust in a deterministic sensitivity analysis except when median time to progression of second-line therapies and administration cost of PLD/carboplatin per administration cycle were varied. The probability of cost-effectiveness for PLD/carboplatin combination was 49.4% at a willingness to pay $20,000. Conclusion: A PLD/carboplatin combination is an economically valuable option as second-line chemotherapy for the treatment of platinum-sensitive ovarian cancer in South Korea.

AB - Objective: We performed a cost-utility analysis to assess the cost-effectiveness of a chemotherapy sequence including a combination of polyethylene glycolated liposomal doxorubicin (PLD)/carboplatin versus paclitaxel/carboplatin as a second-line treatment in women with platinum-sensitive ovarian cancer. Methods: A Markov model was constructed with a 10-year time horizon. The treatment sequence consisted of first- to sixth-line chemotherapies and best supportive care (BSC) before death. Cycle length, a time interval for efficacy evaluation of chemotherapy, was 9 weeks. The model consisted of four health states: responsive, progressive, clinical remission, and death. At any given time, a patient may have remained on a current therapy or made a transition to the next therapy or death. Median time to progressions and overall survivals data were obtained through a systematic literature review and were pooled using a meta-analytical approach. If unavailable, this was elicited from an expert panel (eg, BSC). These outcomes were converted to transition probabilities using an appropriate formula. Direct costs included drug-acquisition costs for chemotherapies, premedication, adverse-event treatment and monitoring, efficacy evaluation, BSC, drug administration, and follow-up tests during remission. Indirect costs were transportation expenses. Utilities were also derived from the literature. Costs and utilities were discounted at an annual rate of 5% per cycle. Results: PLD/carboplatin combination as the second line in the sequence is more effective and costly than paclitaxel/carboplatin combination, showing an additional US$21,658 per quality-adjusted life years. This result was robust in a deterministic sensitivity analysis except when median time to progression of second-line therapies and administration cost of PLD/carboplatin per administration cycle were varied. The probability of cost-effectiveness for PLD/carboplatin combination was 49.4% at a willingness to pay $20,000. Conclusion: A PLD/carboplatin combination is an economically valuable option as second-line chemotherapy for the treatment of platinum-sensitive ovarian cancer in South Korea.

UR - http://www.scopus.com/inward/record.url?scp=84879716911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879716911&partnerID=8YFLogxK

U2 - 10.2147/CEOR.S42170

DO - 10.2147/CEOR.S42170

M3 - Article

C2 - 23869171

AN - SCOPUS:84879716911

VL - 5

SP - 297

EP - 307

JO - ClinicoEconomics and Outcomes Research

JF - ClinicoEconomics and Outcomes Research

SN - 1178-6981

IS - 1

ER -